Literature DB >> 24249036

Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Yakup Kulu1, Beat Müller-Stich, Markus W Büchler, Alexis Ulrich.   

Abstract

BACKGROUND: Selected patients with peritoneal surface malignancies (PSM) have been treated effectively by the combination of cytoreduction surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
PURPOSE: The purpose of this study is to summarize the treatment outcomes and general considerations regarding definitions and staging systems of current CRS and HIPEC modalities in malignant peritoneal mesothelioma and in secondary peritoneal malignancies such as peritoneal metastasis from appendiceal, colorectal, gastric, and epithelial ovarian cancers.
CONCLUSION: Disease progression within the peritoneal cavity has in the past been regarded as a terminal event. Accumulating evidence underlines the therapeutic potential and the acceptable morbidity and mortality rates of CRS and HIPEC in selected patients.

Entities:  

Mesh:

Year:  2013        PMID: 24249036     DOI: 10.1007/s00423-013-1144-8

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  91 in total

1.  Is the peritoneum a significant transport barrier in peritoneal dialysis?

Authors:  Michael Flessner; Jeffrey Henegar; Steven Bigler; Lori Genous
Journal:  Perit Dial Int       Date:  2003 Nov-Dec       Impact factor: 1.756

2.  An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution.

Authors:  Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2005-11-01       Impact factor: 3.454

Review 3.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

Review 4.  Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach.

Authors:  Paul H Sugarbaker
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 5.  Epidemiology of peritoneal mesothelioma: a review.

Authors:  P Boffetta
Journal:  Ann Oncol       Date:  2006-10-09       Impact factor: 32.976

Review 6.  Systematic review of the Sugarbaker procedure for pseudomyxoma peritonei.

Authors:  J Bryant; A J Clegg; M K Sidhu; H Brodin; P Royle; P Davidson
Journal:  Br J Surg       Date:  2005-02       Impact factor: 6.939

Review 7.  Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis.

Authors:  Katherine McBride; David McFadden; Turner Osler
Journal:  J Surg Res       Date:  2013-01-10       Impact factor: 2.192

8.  Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgery.

Authors:  Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2010-03-01       Impact factor: 3.454

9.  Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.

Authors:  Andrew L Feldman; Steven K Libutti; James F Pingpank; David L Bartlett; Tatiana H Beresnev; Sharon M Mavroukakis; Seth M Steinberg; David J Liewehr; David E Kleiner; H Richard Alexander
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

10.  Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Rhonda L Harmon; Paul H Sugarbaker
Journal:  Int Semin Surg Oncol       Date:  2005-02-08
View more
  5 in total

1.  Management of Peritoneal Carcinomatosis With Cytoreductive Surgery Combined With Intraperitoneal Chemohyperthermia at a Novel Italian Center.

Authors:  Pinuccia Faviana; Laura Boldrini; Barbara Musco; Mauro Ferrari; Alfonso Greco; Lorenzo Fornaro; Gianluca Masi; Francesco Forfori; Sergio Ricci; Augusto Brogi; Fulvio Basolo; Alfredo Falcone; Angelo Gadducci; Piero Vincenzo Lippolis
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative.

Authors:  Mohammad Y Zaidi; Rachel M Lee; Adriana C Gamboa; Shelby Speegle; Jordan M Cloyd; Charles Kimbrough; Travis Grotz; Jennifer Leiting; Keith Fournier; Andrew J Lee; Sean Dineen; Sophie Dessureault; Kaitlyn J Kelly; Nikhil V Kotha; Callisia Clarke; T Clark Gamblin; Sameer H Patel; Tiffany C Lee; Ryan J Hendrix; Laura Lambert; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Andrew M Blakely; Byrne Lee; Fabian M Johnston; Nadege Fackche; Maria C Russell; Shishir K Maithel; Charles A Staley
Journal:  Ann Surg Oncol       Date:  2019-10-10       Impact factor: 5.344

3.  Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study.

Authors:  Susanne Roth; Christoph Springfeld; Markus K Diener; Christine Tjaden; Phillip Knebel; Ulla Klaiber; Christoph W Michalski; Markus Mieth; Dirk Jäger; Markus W Büchler; Thilo Hackert
Journal:  BMJ Open       Date:  2019-08-20       Impact factor: 2.692

4.  Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer.

Authors:  Anqiang Wang; Zhongwu Li; Qian Wang; Yali Bai; Xin Ji; Tao Fu; Ke Ji; Yanwen Xue; Tingxu Han; Xiaojiang Wu; Ji Zhang; Yingjie Yang; Guobin Xu; Zhaode Bu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2019-12       Impact factor: 5.087

5.  Nanovehicles as a novel target strategy for hyperthermic intraperitoneal chemotherapy: a multidisciplinary study of peritoneal carcinomatosis.

Authors:  Maciej Nowacki; Marek Wisniewski; Karolina Werengowska-Ciecwierz; Katarzyna Roszek; Joanna Czarnecka; I Łakomska; Tomasz Kloskowski; Dominik Tyloch; Robert Debski; Katarzyna Pietkun; Marta Pokrywczynska; Dariusz Grzanka; Rafał Czajkowski; Gerard Drewa; A Jundziłł; Joseph K Agyin; Samy L Habib; Artur P Terzyk; Tomasz Drewa
Journal:  Oncotarget       Date:  2015-09-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.